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ABSTRACT
Introduction: Ceftobiprole is a fifth-generation cephalosporin with a broad spectrum of antimicro-
bial activity, including also methicillin-resistant Staphylococcus aureus (MRSA). Ceftobiprole is
approved for the treatment of community-acquired pneumonia (CAP) and hospital-acquired pneu-
monia (HAP), excluding ventilator-associated pneumonia, in several European and non-European
countries.
Areas covered: In this narrative review, we discuss the current place in therapy of ceftobiprole, both within
and outside approved indications. An inductive MEDLINE/PubMed search of the available literature was
conducted.
Expert opinion: There are three main reasons which render ceftobiprole an attractive option for
the empirical and targeted treatment of CAP and HAP: (i) its broad spectrum of activity; (ii) its
activity against MRSA; (iii) its good safety profile. For these indications, ceftobiprole should be
employed thoughtfully, in those scenarios in which its intrinsic advantages could be maximized.
The use of ceftobiprole outside approved indications could be justified in specific scenarios, such
as when other approved alternatives are ineffective, when the risk of toxicity due to other agents
is unacceptable, and for salvage therapy. In the near future, ongoing phase 3 studies and further
observational experiences could both enlarge the current panel of approved indications and
enrich our knowledge on the use of ceftobiprole for off-label indications.
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Ceftobiprole is a fifth-generation cephalosporin with a wide
spectrum of antimicrobial activity, including various Gram-posi-
tive and Gram-negative bacteria [1,2]. One of the preeminent
features of ceftobiprole is its activity against methicillin-resis-
tant Staphylococcus aureus (MRSA) [3], a peculiarity of a very few
β-lactams, that could represent an important advantage in
specific scenarios.
Ceftobiprole is approved for the treatment of community-
acquired pneumonia (CAP) and hospital-acquired pneumonia
(HAP), excluding ventilator-associated pneumonia (VAP), in several
European and non-European countries [4–6]. In this narrative
review, we discuss its current place in therapy in light of the
available literature, both within and outside approved indications.
2. Methods
During a remote meeting on December 2018, the struc-
ture of the present narrative review was decided, and
divided in the following main chapters: (i) antimicrobial
properties of ceftobiprole; (ii) pharmacological properties
of ceftobiprole; (iii) use of ceftobiprole for pneumonia; (iv)
use of ceftobiprole for other indications; (v) safety and
tolerability of ceftobiprole. Subsequently, an inductive
MEDLINE/PubMed search for relevant publications was
conducted, using various combinations of dedicated key-
words for each topic. Then, different teams of authors
produced separated drafts addressing the different topics,
that were later merged in a final manuscript reviewed and
approved by all authors.
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3. Antimicrobial properties of ceftobiprole
Ceftobiprole is an expanded-spectrum cephalosporin which,
like other β-lactams, exerts its antibacterial activity by inhibition
of the transpeptidase moiety of the penicillin binding proteins
(PBPs). It exhibits tight binding to several different PBPs of
Gram-positive and Gram-negative pathogens, and a most nota-
ble feature is the ability to inhibit also the PBPs that are resistant
or poorly susceptible to conventional β-lactams, including
PBP2a of methicillin-resistant Staphylococcus aureus (MRSA)
and PBP2x of penicillin-resistant pneumococci (PRP) [1–3].
Concerning β-lactamases, ceftobiprole is stable to the PC1
staphylococcal penicillinase, to the class A broad-spectrum β-
lactamases of the TEM type (less so to those of the SHV type
and to the K1 β-lactamase of Klebsiella oxytoca), and to the
chromosomal AmpC-type β-lactamases of Enterobacterales and
P. aeruginosa. Similar to third- and fourth generation cephalos-
porins, ceftobiprole is degraded by class A extended-spectrum β-
lactamases (ESBLs) (e. g. CTX-M-15) and by carbapenemases
(both serine-carbapenemases, such as KPC-2, and metallo-carba-
penemases, such as IMP-1 and VIM-2), and is also degraded by
some class D enzymes (e. g. OXA-10) [7].
Altogether, these features account for a broad spectrum of
antimicrobial activity which covers staphylococci (including
methicillin-resistant strains of S. aureus and of coagulase-negative
staphylococci), streptococci (including PRP strains), Haemophilus
influenzae, Moraxella catarrhalis, most members of the order
Enterobacterales, and also P. aeruginosa and Enterococcus faecalis.
On the other hand, ceftobiprole has reduced or no activity against
Enterococcus faecium, Acinetobacter baumannii, Burkholderia cepa-
cia complex, Stenotrophomonas maltophilia, Proteus vulgaris, most
Gram-negative anaerobes (e. g. Bacteroides fragilis group and
Prevotella spp.), and strains of Enterobacterales producing acquired
ESBLs or carbapenemases [2,8–10]. The activity against methicillin-
resistant staphylococci and PRP, which is outstanding compared
to that of conventional β-lactams, has led to classification of
ceftobiprole among the fifth generation of cephalosporins [11].
Large surveillance studies carried out during the past decade
on clinical isolates from different geographic regions have
shown a remarkable activity of ceftobiprole against staphylo-
cocci and pneumococci, including methicillin-resistant and
penicillin-resistant isolates, respectively. In particular, for
MRSA and pneumococci, MIC90 values of 2 and 0.5 mg/L,
respectively, have been reported, with susceptibility rates con-
sistently exceeding 95% and 99%, respectively (Table 1). Strains
of MRSA resistant to ceftobiprole are uncommon, and usually
exhibit an MIC of 4 mg/L, i. e. only two-fold higher than the
EUCAST breakpoint for susceptibility (European Committee on
Antimicrobial Susceptibility Testing [EUCAST] clinical break-
point tables, version 9.0, 2019; http://www.eucast.org) [12–16].
Against Enterobacterales, MIC90 values ≥16 mg/L have been
reported, with variable susceptibility rates (Table 1) [12–18],
depending on the prevalence of ESBL and carbapenemase
producers. No clinical breakpoints are yet available for CoNS,
streptococci other than pneumococci, E. faecalis, H. influenzae,
M. catarrhalis, and P. aeruginosa. However, considering the
EUCAST PK/PD breakpoint for susceptibility of 4 mg/L and the
MIC90 values of these pathogens (Table 1) [12–18], also these
species could be considered among the potential targets for
this antibiotic.
In vitro studies have shown that ceftobiprole can be syner-
gistic with daptomycin against MSSA, MRSA and methicillin-
resistant Staphylococcus epidermidis strains [19,20] and with
amikacin and levofloxacin against P. aeruginosa [21].
Article highlights
● Ceftobiprole is a fifth-generation cephalosporin with a broad spec-
trum of antimicrobial activity, including also MRSA, and is approved
for the treatment of CAP and HAP, excluding VAP, in several
European and non-European countries.
● On the basis of the high-level evidence provided by RCT, ceftobiprole
is an effective β-lactam option for the treatment of patients with CAP
or HAP, with the notable advantage of anti-MRSA activity.
● In the literature, the use of ceftobiprole for indications other than
pneumonia has been reported in patients with skin and soft tissue
infections, bloodstream infections, infective endocarditis, mediastini-
tis, and osteomyelitis.
In the near future, ongoing RCT and further observational experi-
ences could both enlarge the current panel of approved indica-
tions and enrich our knowledge on its use for off-label
indications...
Table 1. Ceftobiprole activity against clinical isolates of various bacterial species, from large surveillance studies.
Pathogen MIC50 (mg/L) MIC90 (mg/L) Susceptible (%)
a References
S. aureus 0.5 1 – 2 99.2 – 100 [12–17]
MRSA 1 – 2 2 96.5 – 100 [12–17]
CoNS 0.5 – 1 1 – 2 n. a. (>90 – 100) [12–14,17]
MR-CoNS 1 1 – 4 n. a. (>90 – 100) [12–15,17]
S. pneumoniae ≤0.06–0.25 0.06–0.5 99.3–99.8 [12–17]











H. influenzae ≤0.06 ≤0.06–0.25 n. a. (>90 – 100) [12–14,16]
M. catarrhalis ≤0.06–0.12 0.12 – >4 n. a. (>90 – 100) [12–14,16]
Enterobacterales ≤0.06 16 – >16 73.8 – 87 [12–17]
P. aeruginosa 2 – 4 8 – >16 n. a. (61.8–86) [12–18]
CoNS, coagulase-negative staphylococci; MIC, minimum inhibitory concentration; MR-CoNS, methicillin-resistant CoNS; MRSA, methicillin-resistant Staphylococcus
aureus.
asusceptibility rates calculated according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical breakpoints, version 9.0, 2019 (www.
eucast.org), from references where the value was reported or could be calculated from the reported MIC data; n.a., not applicable, due to the lack of clinical
breakpoints. Values in parentheses are susceptibility rates considering the EUCAST PK/PD breakpoint for susceptibility of 4 mg/L (www.eucast.org).
690 D. R. GIACOBBE ET AL.
Ceftobiprole was also shown to have notable activity
against methicillin-susceptible and methicillin-resistant strains
of S. aureus and S. epidermidis grown as biofilms, alone and in
combination with rifampin or vancomycin [22], suggesting
potential activity against infections associated with biofilm
growth (e.g. infections of devices). Indeed, ceftobiprole
showed remarkable activity against staphylococcal isolates
from foreign body-associated infections and prosthetic joint
infections [23,24].
4. Pharmacological properties of ceftobiprole
Ceftobiprole is the active moiety of the water-soluble prodrug
ceftobiprole medocaril, which is rapidly activated in plasma by
type A esterases [25,26].
Similar to other cephalosporins, ceftobiprole exhibits time-
dependent antibacterial activity. It has been shown in experimen-
tal infection models that maintenance of plasma concentrations
above the MIC for 30% to 60% of the dosing interval (t> MIC) may
guarantee effective bactericidal activity, in terms of >2–3 log10
decrease in CFU over 24 h, against S. aureus, S. pneumoniae and
wild-type Enterobacterales [27]. Noteworthy, the pharmacody-
namic target of ceftobiprole against S. aureus in experimental
pneumonia models was very similar (t> MIC of 40%) among
phenotypically diverse strains (methicillin-susceptible S. aureus,
community-associated (CA)-MRSA and healthcare-acquired (HA)-
MRSA) [28].
Ceftobiprole is administered intravenously at the dosage
of 500 mg q8h infused over 2 h. The pharmacokinetic para-
meters of ceftobiprole in healthy volunteers are summarized
in Table 2 [25,29]. Similar to several other beta-lactams,
ceftobiprole is poorly bound to plasma protein (16%) and
has a Vd which is similar to the extracellular compartment.
Penetration of ceftobiprole was evaluated into the epithelial
lining fluid (ELF) and into soft tissues of healthy volunteers.
Mean penetration (calculated as tissue-to-plasma AUCs ratio)
was 25.5% into the ELF [30], 69% and 49% into skeletal
muscle and adipose tissue, respectively [31]. Ceftobiprole
has a low potential for drug–drug interaction, a short elim-
ination half-life and is excreted almost completely as unmo-
dified moiety by the renal route. Dosage adjustments are
needed in patients with renal impairment (500 mg q12h
over 2 h, 250 mg q12h over 2 h, 250 q24h over 2 h in
presence of CLCr 30–50 mL/min, <30 mL/min and end stage
renal disease or intermittent hemodialysis, respectively) [32].
A recent PK analysis carried out in a single case of critically
ill patient undergoing continuous-veno-venous-hemodiafil-
tration (CVVHDF) suggested that a ceftobiprole dosage of
250 mg q12h over 2 h may allow appropriate target attain-
ment in terms of maintenance of 100% t> MIC [33]. In
patients with augmented renal clearance (>130 mL/min/
1.73 m2), the infusion time of ceftobiprole must be extended
up to 4 h for optimizing drug exposure [29,32].
The relationship between ceftobiprole exposure and micro-
biological and/or clinical outcomeswas analyzed in patients with
nosocomial pneumonia by using data from a randomized dou-
ble-blind phase 3 clinical trial [34]. Multiple logistic regression
analysis showed a strong correlation, and CART analysis deter-
mined that the percentage of t> MIC needed for obtaining
favorable clinical outcome was of 51% of the dosing interval, a
value which is in line with those found in preclinical models [34].
A Monte Carlo simulation showed that at this percentage of t>
MIC, pharmacokinetic data coming fromphase 1 study in healthy
volunteers accurately predicted the actual clinical exposure to
ceftobiprole in patients who were enrolled in the phase 3 noso-
comial pneumonia study, the difference being very small (3.5%
for PK-sampled patients) [35].
A recent population pharmacokinetic/pharmacodynamic
analysis demonstrated that at the standard ceftobiprole dose
of 500 mg every 8 h as a 2-h infusion no pharmacokinetic or
pharmacodynamic differences existed between Asian and non-
Asian subjects, considering that, at a pharmacodynamic target
of 60% t> MIC of the dosing interval, more than 90% of the
population was adequately exposed in both subgroups [36].
5. Use of ceftobiprole in patients with pneumonia
Within in-label indications, ceftobiprole is an important option
for the empirical treatment of patients with CAP and HAP, given
its activity against MRSA, Enterobacterales, and P. aeruginosa.
The approval of ceftobiprole for CAP and HAP is based on two
phase 3 randomized controlled trials (RCT) [37,38]. The first one,
published in 2011, was a non-inferiority, double-blind RCT com-
paring ceftobiprole vs. ceftriaxone (plus optional linezolid, based
on investigators’ suspicion of MRSA involvement) for the treat-
ment of severe CAP requiring hospitalization and intravenous
treatment [38]. Ceftobiprole was administered q8h at 500 mg
over a 120-min infusion, whereas ceftriaxone was administered
once-daily at 2 g over a 30-min infusion. The minimum target
duration of therapy was 7 days in both arms, with optional step-
down to oral cefuroxime at day 3 in case of significant improve-
ment. The primary efficacy endpoint was clinical cure (defined
either as resolution of signs and symptoms of infection or as
sufficient improvement rendering continuation of antibacterial
therapy unnecessary) at the test-of-cure (TOC) visit (7–14 days
after the end of treatment) in the intention-to-treat (ITT) and the
clinically evaluable (CE) populations. Overall, 706 patients were
enrolled, 638 of whomwere included in the ITT population. The CE
population consisted of 469 patients. Clinical cure was achieved in
76.4% (240/314) and 79.3% (257/324) of ITT patients treated with
ceftobiprole and with ceftriaxone ± linezolid, respectively (differ-
ence −2.9%, 95% confidence interval [CI] −9.3 to 3.6), and in 86.6%
(200/231) and 87.4% (208/238) of CE patients treated with cefto-
biprole and with ceftriaxone ± linezolid, respectively (difference
−0.8%, 95% CI −6.9 to 5.3), meeting non-inferiority in both popu-
lations according to the pre-fixed 10% non-inferiority margin [38].
Table 2. Pharmacokinetic (PK) parameters of ceftobiprole after single 500 mg
intravenous dose over 2 h infusion in healthy volunteers [25,29].
PK parameter
Cmax (mg/L) 29.2 ± 5.52
Protein binding (%) 16.0
Vd (L) 21.7 ± 3.3
t1/2 (h) 3.1 ± 0.3
AUC0-∞ (mg⋅h/L) 104.0 ± 13.9
CLT (L/h) 4.89 ± 0.69
CLR (L/h) 4.08 ± 0.72
Urinary excretion (%) 83.1 ± 9.1
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The second registrative study, published in 2014, was a non-
inferiority, double-blind, RCT comparing ceftobiprole vs. ceftazi-
dime plus linezolid for the treatment of HAP and VAP [37].
Ceftobiprole was administered q8h at 500 mg over a 120-min
infusion, ceftazidime was administered q8h at 2 g over a 120-
min infusion, and linezolid was administered q12h at 600 mg over
a 60-min infusion. The planned treatment duration was 7 days,
with a maximum of 14 days. The primary efficacy endpoint was
clinical cure (defined either as resolution of signs and symptoms of
infection or as sufficient improvement rendering continuation of
antibacterial therapy unnecessary) at the TOC visit (7–14 days after
the end of treatment) in the ITT and in the CE populations. The ITT
and CE populations consisted of 781 (571 HAP and 210 VAP) and
495 (383 HAP and 112 VAP) patients, respectively. Clinical curewas
achieved in 59.6% (171/287) and 58.8% (167/284) of ITT patients
with HAP treated with ceftobiprole and with ceftazidime plus
linezolid, respectively (difference 0.8%, 95% CI −7.3 to 8.8), and
in 77.8% (154/198) and 76.2% (141/185) of CE patients treated
with ceftobiprole and with ceftazidime plus linezolid, respectively
(difference 1.6, 95% CI −6.9 to 10.0), meeting non-inferiority in
both populations according to the pre-fixed 15% non-inferiority
margin. Of note, in the CE population HAP patients treated with
ceftobiprole showed a higher rate of early improvement (assessed
at day 4 after the onset of therapy) than HAP patients treated with
ceftazidime plus linezolid (86.9% [172/198] vs. 78.4% [145/185],
respectively, difference 8.5%, 95% CI 0.9 to 16.1), with the largest
difference being observed in patients with MRSA-positive cultures
at baseline (94.7% [18/19] vs. 52.6% [10/19], respectively, differ-
ence 42.1%, 95% CI 17.5 to 66.7) [37].
With regard to VAP patients, clinical cure rates were 23.1%
(24/104) and 36.8% (39/106) in ITT patients treated with ceftobi-
prole and with ceftazidime plus linezolid, respectively (difference
−13.7%, 95% CI −26.0 to −1.0), and in 37.7% (20/53) and 55.9%
(33/59) in CE patients treated with ceftobiprole and with ceftazi-
dime plus linezolid, respectively (difference −18.2%, 95%CI−36.4
to 0.0), failing to demonstrate non-inferiority [37].
The reasons underlying failure in demonstrating non-inferior-
ity of ceftobiprole vs. ceftazidime plus linezolid in patients with
VAP are not perfectly clear. A possible unfavorable effect due to
the presence biofilm-embedded organisms has been hypothe-
sized, which is nonetheless in contrast with the higher rates of
clinical cure observed in ceftobiprole-treated patients than in
ceftazidime plus linezolid-treated patients in the subgroup of
mechanically ventilated HAP (30.4% [21/69] vs. 27.1% [19/70] in
the ITT population, difference 3.3%, 95% CI −11.8 to 18.3, and
55.3% [21/38] vs. 40.5% [15/37] in the CE population, difference
14.7%, 95% CI −7.6 to 37.1) [37]. In addition, ceftobiprole demon-
strated activity in an experimental model of foreign-body infec-
tion [39]. An alternative explanation is the possibly insufficient
attainment of therapeutic concentrations of ceftobiprole in
patients with CLCr ≥150 ml/min, a condition encountered in as
many as 29% of ceftobiprole-treated patients with VAP, and that
might require higher dosages and prolonged infusions to
achieve adequate therapeutic levels [29,32].
As regards post-hoc analyzes of patients with CAP or HAP
in the two major trials, higher rates of early clinical improve-
ment in patients treated with ceftobiprole than in those trea-
ted with comparators were observed overall and especially in
CAP patients aged ≥75 years (difference 16.3%, 95% CI 1.8 to
30.8), CAP patients with chronic obstructive pulmonary dis-
ease (difference 20.1%, 95% CI 8.8 to 31.1), HAP patients
considered to be at higher risk of poor outcomes according
to previous literature (difference 12.5%, 95% CI 3.5 to 21.4),
and HAP patients with >10 baseline comorbidities (difference
15.3%, 95% CI 0.3 to 30.4) [40].
The main findings of the two registrative studies are also
summarized in Table 3. Overall, on the basis of the high-level
evidence provided by RCT, ceftobiprole is an effective β-lac-
tam option for the treatment of patients with CAP or HAP,
with the notable advantage of anti-MRSA and anti-PRP activity
[41]. Conversely, without further high-level evidence from
dedicated RCT, the use of ceftobiprole for VAP cannot be
supported.
6. Use of ceftobiprole for other indications
The use of ceftobiprole outside approved indications could be
justified in specific, non-mutually exclusive scenarios: (i) when
other approved alternatives are ineffective (e.g. resistance); (ii)
when the risk of toxicity or allergic reactions is unacceptable; (iii)
for salvage therapy. In the literature, the use of ceftobiprole for
indications other than pneumonia has been reported in patients
with skin and soft tissue infections, bloodstream infections, infec-
tive endocarditis, mediastinitis, and osteomyelitis [42–47].
6.1. Skin and soft tissue infections
In a mouse subcutaneous abscess model, ceftobiprole showed
a more potent activity than vancomycin or linezolid against
MRSA and VISA [2]. In healthy volunteers, in vivo microdialysis
techniques have evidenced adequate penetration of ceftobi-
prole in soft tissues, with prediction of optimal activity against
organisms with MIC up to 2 mg/L [31].
From 2004 to 2005, a phase 3, non-inferiority, double-blind
RCT was conducted in 129 sites worldwide, in patients with
suspected or documented Gram-positive complicated skin and
soft tissue infections (cSSTI) [46]. Patients were randomized to
receive either ceftobiprole at 500 mg q12h or vancomycin at 1
g q12h. The duration of treatment was 7–14 days. Diabetic
foot infections, bite wound infection, and osteomyelitis were
excluded. The primary endpoint was clinical cure at the TOC
visit (7–14 days after the end of treatment). The non-inferiority
margin was set at 10%. In the ITT population, clinical cure was
achieved in 77.8% (309/397) and 77.5% (300/387) of patients
treated with ceftobiprole and vancomycin, respectively (differ-
ence 0.3%, 95% CI −5.5 to 6.1). In the CE population, clinical
cure was achieved in 93.3% (263/282) and 93.5% (259/277) of
patients treated with ceftobiprole and vancomycin, respec-
tively (difference −0.2%, 95% CI −4.4 to 3.9) [46].
From 2005 to 2006 another phase 3, double-blind, RCT was
conducted in patients with cSSTI caused by either Gram-positive
or Gram-negative bacteria, comparing ceftobiprole vs. vancomy-
cin plus ceftazidime [45]. Ceftobiprole was administered at 500mg
q8h, vancomycin was administered at 1 g q12h, and ceftazidime
was administered at 1 g q8h. The primary endpoint was clinical
cure at the TOC visit (7–14 days after the end of treatment). The
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non-inferiority margin was set at 10%. In the ITT population,
clinical cure was achieved in 81.9% (448/547) and 80.8% (227/
281) of patients treated with ceftobiprole and vancomycin plus
ceftazidime, respectively (difference 1.1%, 95% CI −4.5 to 6.7). In
the CE population, clinical cure was achieved in 90.5% (439/485)
and 90.2% (220/244) of patients treated with ceftobiprole and
vancomycin plus ceftazidime, respectively (difference 0.3%, 95%
CI −4.2 to 4.9) [45].
However, despite the results of these two RCT suggested
that ceftobiprole was beneficial to patients, it should be noted
that authorization for SSTI was ultimately not granted. This
decision was based on the lack of compliance with good
clinical practice (GCP) recommendations registered in some
participating sites in the United States [48]. A novel phase 3,
non-inferiority, double-blind RCT comparing ceftobiprole vs.
vancomycin plus aztreonam for the treatment of acute bacter-
ial skin and skin structure infections (ABSSSI) has been
initiated and is currently ongoing (NCT03137173).
6.2. Bacteremia, endocarditis, and mediastinitis
The interest in using ceftobiprole for the treatment of bacter-
emia and endocarditis is increased by the results of rat and
rabbit models of infective endocarditis (IE) due to MRSA,
which showed a bactericidal effect possibly higher than that
of linezolid and daptomycin [49,50]. Therapy with ceftobiprole
was also successful in a rat model of mediastinitis, induced by
the injection of MRSA into the sternal bone [51]. A higher
reduction in MRSA load after 5 days of therapy was observed
in rats receiving ceftobiprole in comparison with rats receiving
vancomycin. At day 14 of treatment, there was evidence of
complete/most complete MRSA sternal clearance in both cef-
tobiprole-treated and vancomycin-treated rats [51].
Regarding the available evidence in humans, some information
about the efficacy of ceftobiprole for the treatment of staphylo-
coccal bacteremia canbe extrapolated fromexistent RCT. In apost-
hoc pooled analysis of four phase 3 double-blind RCT (two in
patients with cSSTI, one in patients with CAP, and one in patients
withHAP/VAP) [37,38,45,46], whichwaspresented at the European
Society of Clinical Microbiology and Infectious Diseases (ESCMID)
congress in 2016, clinical cure rates and 30-day all-cause mortality
were compared between patients with staphylococcal bacteremia
treated with ceftobiprole and patients with staphylococcal bacter-
emia treated with the different comparators (vancomycin and
vancomycin plus ceftazidime in cSSTI trials, ceftriaxone ± linezolid
in the CAP trial, and ceftazidime plus linezolid in the HAP/VAP trial)
[52]. Cumulatively, 95 patients had staphylococcal bacteremia in
the four RCT. With the limitation of the small sample size, both
clinical cure rates and 30-day all-cause mortality were similar
between patients treated with ceftobiprole and patients treated
with the comparators (for clinical cure, 48.9% [22/45] vs. 44.0% [22/
50], respectively, difference 4.9%, 95% CI −12.2 to 25.0; for 30-day
all-cause mortality, 8.9% [4/45] vs. 16.0% [8/50], respectively, dif-
ference −7.1%, 95%CI−20.2 to 6.0). Of note, a trend toward higher
rates of favorable outcomes was observed in ceftobiprole-treated
vs. comparator/s-treated patients in the subgroup of patients with
MRSA bacteremia, although the very small denominator (n = 18)
precludes generalization (for clinical cure, 55.6% [5/9] vs. 22.2% [2/
9], respectively, difference 33.3%, 95% CI −9.0 to 77.7; for 30-day
all-cause mortality, 0.0% [0/9] vs. 22.2%
[2/9], respectively, difference −22.2%, 95% CI −49.4 to 4.9) [52].
No evidence from RCT is available regarding the efficacy of
ceftobiprole for the treatment of infective endocarditis.
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However, a non-inferiority, double-blind, RCT comparing cef-
tobiprole vs. daptomycin for the treatment of S. aureus bacter-
emia, including right-sided infective endocarditis, is currently
being conducted in adult patients (NCT03138733), and could
open the door to the future approval of ceftobiprole for these
indications should non-inferiority be demonstrated.
With regard to observational studies, 10 episodes of severe
MRSA infection treated with ceftobiprole (of which 7/10 were
bacteremia and 3/10were pneumonia) were reported in a single-
center retrospective case series in Canada [42]. Microbiological
eradication was observed in 9/10 patients treated with ceftobi-
prole, including two bacteremic cases of salvage therapy follow-
ing previous treatment failure with vancomycin, and one
bacteremic case of salvage therapy following previous treatment
failure with linezolid. Of note, breakthrough bacteremia was
observed in a patient in whom ceftobiprole was underdosed
due to a medication error. Overall, a favorable outcome was
observed in 8/10 episodes (80%) [42].
Two case reports describing the successful treatment with
ceftobiprole of patients with IE have also been published [43,47].
The first case involved a patient with severe pancytopenia after
autologous hematopoietic stem cells transplantation (HSCT) for
Burkitt lymphoma and recurrent bacteremia due to methicillin-
resistant Staphylococcus epidermidis (MRSE) in presence of a pros-
thetic endovascular infection of the aortic valve and the ascending
aorta, which responded favorably to ceftobiprole monotherapy
[43]. After blood cultures turned negative, the patient underwent
halogenic HSCT without episodes of breakthrough bacteremia in
the postoperative period. Ceftobiprole was discontinued 3
months after allogeneic HSCT, and no radiological or clinical
signs of infection were detected during a 1-year follow-up [43].
The second case involved a patient with renal insufficiency
and aortic valve replacement complicated byMRSAmediastinitis
[47]. After several failed courses of antimicrobials, a combination
regimen of daptomycin plus ceftobiprole was initiated, with
favorable response (the patient became afebrile) and subse-
quent valve surgery [47]. The use of combination therapy (cefto-
biprole plus daptomycin) was in line with in vitro studies
reporting a potent synergy between ceftobiprole and daptomy-
cin [19,20]. This is an intriguing possibility to be further investi-
gated in clinical studies, since it could represent an important
option for salvage therapy of MRSA bacteremia and/or endocar-
ditis. Of note, synergy between ceftobiprole and daptomycin has
also been demonstrated against enterococci, including vanco-
mycin-resistant isolates [20,53]. However, the related evidence is
currently limited to in vitro studies, and further evidence from
either animal models or clinical studies is needed regarding the
possible use of ceftobiprole/daptomycin combinations for
severe enterococcal infections in humans.
6.3. Osteomyelitis
Ceftobiprole showed potent activity against MRSA and methi-
cillin-resistant coagulase-negative staphylococci isolates from
bone and joint infections in an in vitro study, as well as in a
rabbit model of CA-MRSA osteomyelitis [54,55]. The interest in
using ceftobiprole for osteomyelitis and prosthetic joint infec-
tions also relies of its synergy with rifampin observed against
biofilms [22].
An experience about the use of ceftobiprole for osteomyelitis
was reported in 2010 [44]. A diabetic patient with a septic arthritis
and bone destruction, with MRSA and Peptostreptococcus prevotii
isolation and involving both the second and third metatarsopha-
langeal joints at the right foot, was initially treated with vancomy-
cin and piperacillin/tazobactam, later replaced by ceftobiprole
monotherapy due to kidney failure [44]. The patient underwent
excision of the second and third metatarsal heads and was suc-
cessfully treated with intravenous ceftobiprole for a total duration
of 42 days including the postoperative period, with no evidence of
relapsed osteomyelitis after a 1-year follow-up [44]. However,
there could have been a major role of infected tissue removal in
favorably influencing clinical cure, thus more supportive clinical
evidence is warranted.
7. Safety and tolerability of ceftobiprole
Safety and tolerability of ceftobiprole were first assessed in phase
1 trials [26,56]. In a single dose-increasing study, caramel-like
dysgeusia, attributable to a diacetyl product of conversion, was
the only relevant mild adverse event (AE) observed [26]. In two
subsequent phase 1 trials, nausea, vomiting and headache were
reported as dose-related events [57].
Data from phase 2 and phase 3 studies involved a total of
3037 patients (1668 receiving ceftobiprole and 1369 receiving
the comparator/s) [58]. Pooled data from pneumonia studies
included a total of 1404 patients (696 receiving ceftobiprole
and 708 the comparator/s). Ceftobiprole was generally well tol-
erated with a low discontinuation rate due to AE drug-related,
similar to that observed with the comparator/s (10.3% vs. 7.3%
for ceftobiprole vs. comparator/s, overall; 14.0% vs. 10.4% in the
HAP/VAP phase 3 trial and 5.8% vs. 3.7% in the CAP phase 3
trials). Most patients reported at least one AE (74.1% in the
ceftobiprole and 71.8% comparator arm, respectively), with
rates being 77.5% in the ceftobiprole arm vs. 77.7% in the
comparators arm in the HAP/VAP trial, and 70.0% in the ceftobi-
prole arm vs. 64.6% in the comparator/s arm in the CAP trial [58].
Overall, the most common AEs (≥3% of patients) reported
with ceftobiprole from the pooled analysis of HAP, CAP or
cSSTI studies were nausea, vomiting, diarrhea, infusion site
reactions, dysgeusia and drug-related hypersensitivity (urti-
caria, pruritus, and rash) [58].
In the phase 3 CAP RCT, the overall AE rate was 36% in the
ceftobiprole group vs. 26% in the ceftriaxone ± linezolid com-
parator group [38]. This difference was mainly related to
higher occurrence of nausea (7% vs. 2%) and vomiting (5%
vs. 2%) in the ceftobiprole group, whereas occurrence of
injection-site AEs (7% vs. 5%), hyponatremia (1% vs. 3%) and
hepatic AEs (7% vs. 7%) were similar in both groups.
In the phase 3 HAP/VAP RCT the overall AE rate was 24.9%
in the ceftobiprole group vs. 25.4% in the ceftazidime plus
linezolid group [37]. Diarrhea was less frequently reported in
the ceftobiprole arm (3.1% and 6.5%), whereas hyponatremia
was more frequent in patients treated with ceftobiprole than
in those receiving the comparators (4.4% and 2.6%, respec-
tively). In patients treated with ceftobiprole, dysgeusia
occurred only in 1.3% of cases. No other clinically relevant
differences in laboratory values, vital signs, physical
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examinations, or electrocardiograms were observed between
the treatment arms.
Overall, Clostridioides difficile colitis was rare in ceftobiprole-
treated patients in RCT. This is possibly related to the valid
inhibitory activity that ceftobiprole exhibits against C. difficile
[59]. This hypothesis is supported by the fact that ceftobiprole
was shown to have no significant ecological impact on the
human intestinal microflora of healthy volunteers [60].
Additionally, in experimental models, ceftobiprole did not
promote neither growth of nor toxin production by C. difficile
in mouse cecal contents, differently from what occurred with
other cephalosporins (ceftazidime, cefoxitin, ceftriaxone, cefo-
taxime) and with carbapenems (ertapenem) [59].
8. Conclusion
Ceftobiprole is an important option for the treatment of CAP
and HAP when MRSA is suspected or involved. In the near
future, ongoing RCT and further observational experiences
could both enlarge the current panel of approved indications
and enrich our knowledge on its use for off-label indications.
9. Expert opinion
There are three main and non-mutually exclusive reasons
which render ceftobiprole an attractive option for the empiri-
cal and targeted treatment of CAP and HAP: (i) its broad
spectrum of activity; (ii) its activity against MRSA; (iii) its
good safety profile. For example, these advantages should
be taken into account when dealing with HAP in hospitalized
patients with multiple comorbidities and at risk both of MRSA
infection and of adverse events due non-β-lactam anti-MRSA
agents. Another suitable scenario for ceftobiprole therapy
could be that of severe CAP complicating influenza, in which
empirical coverage of CA-MRSA should be guaranteed [61]. On
the other hand, costs and antimicrobial stewardship principles
(which dictate against the use of anti-MRSA agents in absence
of substantial risk, in order to avoid useless selective pressure)
indicate that ceftobiprole should not be overused, but rather
employed thoughtfully in those scenarios in which its intrinsic
advantages could be maximized. Based on these premises, a
potential treatment algorithm for guiding clinicians’ decisions
regarding the use of ceftobiprole in CAP and HAP is depicted
in Figure 1.
Another framework in which ceftobiprole could represent a
reasonable choice at the present time is the salvage therapy of
bacteremia and endocarditis (despite not approved) due to
MRSA after failure of vancomycin or daptomycin therapy. In
such a case, the possible advantage of a salvage combination
of ceftobiprole plus either daptomycin or vancomycin lies in
the synergy observed in vitro studies [11], for which several
possible mechanisms have been described. Amongst others
are the reduced expression of the mecA gene and the inhibi-
tory effect on the early stages of the peptidoglycan synthesis
by daptomycin [62], the reduction in the cell surface charge by
β-lactams that might favor daptomycin binding [63], and the
seesaw effect enhancing activity of β-lactams in case of iso-
lates with increased daptomycin or vancomycin MIC [11,64]. It
should nonetheless be noted that, despite the use this strat-
egy could be considered after failure of standard therapy, the
related evidence from clinical studies remains limited, and
further experience is thus warranted to determine its true
efficacy. Notably, also the use of ceftobiprole monotherapy
may be considered in the future for the treatment of MRSA
bacteremia, not only as salvage therapy but also possibly as a
primary therapeutic approach, in case of favorable results from
ongoing RCT (NCT03138733). The possible synergistic activity
of ceftobiprole and daptomycin against some strains of
Figure 1. Algorithm illustrating the possible use of ceftobiprole for empirical therapy in patients with CAP and HAP (non-VAP).
CAP, community-acquired pneumonia; ESBL, extended-spectrum β-lactamases; HAP, hospital-acquired pneumonia; MRSA, methicillin-resistant Staphylococcus aureus; VAP, ventilator-
associated pneumonia.
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vancomycin-resistant enterococci, suggested in a preliminary
in vitro study, deserves further investigation [65].
In the next five years, we expect to witness an increasing
number of observational studies and case reports about the
use of ceftobiprole for currently off-label indications such as
bacteremia, endocarditis, osteomyelitis, and mediastinitis. In
addition, results of phase 3 RCT on ABSSSI and S. aureus
bacteremia (NCT03137173 and NCT03138733) are much
awaited and may provide important high-evidence efficacy
data regarding the use of ceftobiprole for these potential,
additional indications.
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